Washington, DC 20549


                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

         Date of report (Date of earliest event reported): June 18, 2003

                               CYTOGEN CORPORATION
               (Exact Name of Registrant as Specified in Charter)

           Delaware                     000-14879                 222322400
(State or Other Jurisdiction    (Commission File Number)       (IRS Employer
      of Incorporation)                                      Identification No.)

650 College Road East, Suite 3100, Princeton, NJ                        08540
(Address of Principal Executive Offices)                              (Zip Code)

                                 (609) 750-8200
                         (Registrant's telephone number,
                              including area code)

          (Former Name or Former Address, if Changed Since Last Report)

         Item 5.   Other Events and Required FD Disclosure.

On June 18, 2003,  Advanced Magnetics,  Inc. ("Advanced  Magnetics") and Cytogen
Corporation ("Cytogen") announced in a press release the publication of clinical
data in the New England  Journal of Medicine  showing  that  magnetic  resonance
imaging  with  Combidex(R),   Advanced  Magnetic's  investigational  iron  oxide
nanoparticle used to aid in the diagnosis of lymph node disease,  allows for the
noninvasive  assessment of lymph nodes in patients with prostate cancer. Cytogen
has a  license  with  Advanced  Magnetics  for  exclusive  marketing  rights  to
Combidex(R) in the United States.

Such press release is attached hereto as Exhibit 99.1 and is incorporated herein
by reference.  The foregoing  description  of such press release is qualified in
its entirety by reference to such document.

         Item 7.   Financial Statements, Pro Forma Financial Information and

         (c) Exhibits.

               Exhibit No.       Description
               -----------       -----------

                   99.1          Press release dated June 18, 2003


         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                   Cytogen Corporation

                                   By: /s/ Michael D. Becker
                                        Michael D. Becker,
                                        President and Chief Executive Officer

Date:  July 3, 2003